SCHEMBL6992950

SCHEMBL6992950

CC(=O)CN1C(=O)c2cc(Cl)ccc2S1(=O)=O

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA12 O43570 8/20 0.65
CA9 Q16790 7/20 0.65
CA2 P00918 5/20 0.65
PAX8 Q06710 2/20 0.56
CA1 P00915 2/20 0.56
KLF5 Q13887 1/20 0.56
RAB9A P51151 6/20 0.47
HSP90AA1 P07900 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
ADRA1D P25100 5/20 0.46
ADRA1A P35348 5/20 0.46
ADRA1B P35368 4/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6992444 0.89 CA12 (0.65) CA12CA9CA2PAX8CA1
SCHEMBL11487413 0.85 CA12 (0.53) CA12CA9CA2PAX8CA1
SCHEMBL8047935 0.84 ADRA1D (0.52) CA12CA9CA2PAX8CA1
SCHEMBL10883408 0.81 CA12 (0.46) CA12CA9CA2PAX8CA1
SCHEMBL10882364 0.81 CA12 (0.46) CA12CA9CA2PAX8CA1
SCHEMBL6996990 0.81 CA12 (0.62) CA12CA9CA2PAX8CA1
SCHEMBL10908945 0.79 CA12 (1.00) CA12CA9CA2PAX8CA1
SCHEMBL28838466 0.73 CA9 (0.58) CA12CA9CA2PAX8CA1
SCHEMBL7815416 0.73 ADRA1D (0.51) CA12CA9CA2PAX8CA1
SCHEMBL8047941 0.73 ADRA1D (0.41) CA12CA9CA2PAX8CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6664251-B2 Serotonin receptor antagonist; treating cardiovascular disorder DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2003-12-16 US disclosed
US-20030078256-A1 Benzothiazine derivative SUNTORY LIMITED (JP) 2003-04-24 US disclosed
EP-0749967-B1 Substituted benzothiazine derivative SUNTORY LTD (JP) 2003-01-22 EP disclosed
US-6316442-B1 TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES SUNTORY LIMITED (JP) 2001-11-13 US disclosed
US-6001827-A Benzothiazine derivative SUNTORY LIMITED (JP) 1999-12-14 US disclosed
US-5874429-A ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS SUNTORY LIMITED (JP) 1999-02-23 US disclosed
EP-0749967-A1 Substituted benzothiazine derivative SUNTORY LIMITED (JP) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078256-A1 Benzothiazine derivative TPH2, ADRB2, TPH1 CA12 4559/4885CA9 4680/4885CA2 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.